PharmaCyte Biotech, Inc.

PMCB

US71715X2036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.11 ^USD	-0.47%		-0.47%	-2.31%

Mar. 18	PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
2023	PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	CI

PharmaCyte Biotech, Inc. announced that it has received $35 million in funding

May 09, 2023

On May 10, 2023, PharmaCyte Biotech, Inc., closed the transaction. The company has raised a total of $35 million in the transaction.

Latest news about PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 18	CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 15	CI
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors	Nov. 21	CI
Femasys Inc. announces tranche update	Nov. 16	CI
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc.	Nov. 13	CI
PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology	23-10-31	CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.	23-09-18	CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-18	CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.	23-07-31	CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	23-07-31	CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on May 11, 2023.	23-06-15	CI
PharmaCyte Biotech, Inc.'s Equity Buyback announced on May 11, 2023, has closed with 8,085,879 shares, representing 48.15% for $26.46 million.	23-06-08	CI
PharmaCyte Biotech, Inc. announces an Equity Buyback for 7,750,000 shares, for $25.19 million.	23-05-11	CI
PharmaCyte Biotech, Inc authorizes a Buyback Plan.	23-05-10	CI
PharmaCyte Biotech, Inc. announced that it has received $35 million in funding	23-05-09	CI
PharmaCyte Biotech, Inc. announced that it expects to receive $35 million in funding	23-05-08	CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.	23-03-16	CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on June 2, 2022.	23-03-16	CI
PharmaCyte Biotech, Inc. announces an Equity Buyback for $10 million worth of its shares.	23-02-02	CI
PharmaCyte Biotech, Inc.'s Equity Buyback announced on June 2, 2022, has closed with 3,725,114 shares, representing 18.21% for $10 million.	23-01-30	CI
PharmaCyte Biotech, Inc. authorizes a Buyback Plan.	23-01-30	CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on June 2, 2022.	22-12-14	CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	22-12-14	CI
PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director	22-11-07	CI
PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer	22-10-14	CI

Chart PharmaCyte Biotech, Inc.

Duration

Period

More charts

PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMACYTE BIOTECH, INC.	-2.31%	17.84M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals